These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 20223696)

  • 1. Long term follow-up of Parkinson's disease patients with impulse control disorders.
    Sohtaoğlu M; Demiray DY; Kenangil G; Ozekmekçi S; Erginöz E
    Parkinsonism Relat Disord; 2010 Jun; 16(5):334-7. PubMed ID: 20223696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Impulse control disorders in Parkinson's disease: A cohort of 35 patients].
    Carrière N; Kreisler A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2012 Feb; 168(2):143-51. PubMed ID: 22129474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience.
    Limotai N; Oyama G; Go C; Bernal O; Ong T; Moum SJ; Bhidayasiri R; Foote KD; Bowers D; Ward H; Okun MS
    Int J Neurosci; 2012 Mar; 122(3):145-53. PubMed ID: 22023411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease.
    Perez-Lloret S; Rey MV; Fabre N; Ory F; Spampinato U; Brefel-Courbon C; Montastruc JL; Rascol O
    Clin Neuropharmacol; 2012; 35(6):261-5. PubMed ID: 23123689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
    Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
    Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease.
    Joutsa J; Martikainen K; Vahlberg T; Kaasinen V
    Parkinsonism Relat Disord; 2012 Dec; 18(10):1079-83. PubMed ID: 22784693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compulsive behaviors in patients with Parkinson's disease.
    Kenangil G; Ozekmekçi S; Sohtaoglu M; Erginöz E
    Neurologist; 2010 May; 16(3):192-5. PubMed ID: 20445429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impulse control disorders in Parkinson's disease: prevalence and possible risk factors.
    Weintraub D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S110-3. PubMed ID: 20082968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
    Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impulse control disorders in Parkinson's disease in a Chinese population.
    Fan W; Ding H; Ma J; Chan P
    Neurosci Lett; 2009 Nov; 465(1):6-9. PubMed ID: 19560522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impulse control disorders in Parkinson's disease.
    Vilas D; Pont-Sunyer C; Tolosa E
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S80-4. PubMed ID: 22166463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
    Winge K; Werdelin LM; Nielsen KK; Stimpel H
    Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine agonist withdrawal syndrome in Parkinson disease.
    Rabinak CA; Nirenberg MJ
    Arch Neurol; 2010 Jan; 67(1):58-63. PubMed ID: 20065130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease.
    Hicks CW; Pandya MM; Itin I; Fernandez HH
    Parkinsonism Relat Disord; 2011 Jun; 17(5):379-81. PubMed ID: 21459656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.